Center for Cancer Immunology and Immunotherapy (CCII)

癌症免疫学和免疫治疗中心 (CCII)

• 批准号: 10333205
• 负责人: Jason A. Chesney
• 金额: $ 231.6万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10333205
• 关键词: Adoptive Cell Transfers; Advanced Malignant Neoplasm; Advisory Committees; Animals; Antibodies; Area; Award; Basic Science; Bioinformatics; Biological Markers; Biomedical Research; Biometry; Bladder; CAR T cell therapy; CTLA4 gene; Cancer Center; Cancer Death Rates; Centers of Research Excellence; Clinical; Clinical Trials; Collaborations; Conduct Clinical Trials; Country; Cytometry; Development; Diagnosis; Discipline; Disease remission; Disseminated Malignant Neoplasm; Early Diagnosis; Financial Support; Flow Cytometry; Funding; Future; Genomics; Goals; Grant; Growth; Head and neck structure; Home; Human; Human Resources; Immune; Immune Evasion; Immune checkpoint inhibitor; Immune response; Immune system; Immunity; Immunologic Surveillance; Immunologist; Immunotherapeutic agent; Immunotherapy; Infrastructure; Institution; Interdisciplinary Study; International; Kidney; Lead; Lung; Malignant Neoplasms; Mediating; Mentors; Mission; Molecular; Mus; Names; Oncolytic viruses; Outcome; Paper; Patients; Persons; Phase; Pilot Projects; Proteins; Publications; Recording of previous events; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resistance; Resources; Sampling; Savings; Seminal; Services; Specimen; Study Section; T cell therapy; Talents; Testing; Training; Translating; Translational Research; Universities; Vaccines; Work; anti-cancer; base; cancer cell; cancer clinical trial; cancer immunotherapy; cancer therapy; cancer type; career development; checkpoint therapy; cohort; equipment acquisition; immune checkpoint; improved; innovation; interest; melanoma; member; microbiome research; new therapeutic target; novel strategies; optimism; programmed cell death ligand 1; programmed cell death protein 1; programs; recruit; research and development; response; senior faculty; side effect; success; systemic toxicity; treatment strategy; tumor; tumor immunology

The objective of this program is to establish a thematic multidisciplinary research center of excellence at the University of Louisville (UofL) named the Center for Cancer Immunology and Immunotherapy (CCII). The mission of the CCII is to conduct outstanding biomedical research that works towards harnessing the power of the immune system to eradicate cancer. There is currently a great deal of optimism about the prospects for cancer immunotherapies given the recent clinical successes of immune checkpoint inhibitors, oncolytic viruses, and adoptive cell transfer therapies. Immunotherapies have the potential to be used to treat all types of cancer and to induce long-lasting remissions or cures. However, more research and development is needed for cancer immunotherapy to reach its full potential. The University of Louisville is exceptionally qualified to be the home of the CCII for many reasons including our 10-year track record of conducting clinical trials of immunotherapeutic agents, unique resources that include access to human specimens from these trials, our senior investigators’ expertise in cancer immunology, our focus on translational research, and the impact that this COBRE would have in a state with the highest cancer death rates in the nation. Importantly, the University of Louisville is highly invested in making this proposed center a success as best evidenced by more than $16.8M in institutional commitments over five years. The two PIs of the CCII program are highly regarded experts in the field who have made seminal contributions spanning from basic cancer immunology to pivotal clinical trials of cancer immunotherapies. Senior mentors with expertise in the thematic area and a strong history of funding, publications, mentoring, and study section service will support the CCII’s mentoring mission, as will a team of co-investigators with essential expertise (in administration, biostatistics, and bioinformatics) and Internal and External Advisory Committees. A Functional Immunomics Core will provide important new infrastructure and leverage existing resources (including other IDeA programs) to provide outstanding support to the four promising junior investigators who have been selected as the first cohort of CCII Project PIs. The four overall specific aims of the CCII are to: (1) Establish the administrative and mentoring infrastructure for the CCII; (2) Create a research core that provides new capabilities while leveraging existing facilities; (3) Support the research and career development of junior PIs in the thematic area; and (4) Develop and initiate a plan for long-term sustainability and growth of the CCII. We are confident that this new COBRE center will lead to the awarding of innovative R01 grants for 4-6 CCII junior investigators in the first five years and that many of these graduates will remain key members of this new COBRE to further build the center in the future. Most importantly, our combination of rigorous basic science with highly translational animal and human specimen studies should ultimately contribute to the development of new treatment strategies that will help to improve the outlook for the more than 17 million people worldwide who are diagnosed with cancer each year.

该计划的目标是在该中心建立一个卓越的专题多学科研究中心 路易斯维尔大学 (UofL) 命名为癌症免疫学和免疫治疗中心 (CCII)。这 CCII 的使命是开展杰出的生物医学研究，致力于利用 免疫系统消灭癌症。目前人们对未来的前景非常乐观 鉴于最近免疫检查点抑制剂、溶瘤病毒的临床成功，癌症免疫疗法 和过继性细胞移植疗法。免疫疗法有潜力用于治疗所有类型的癌症 并诱导持久的缓解或治愈。然而，还需要更多的研究和开发 癌症免疫疗法充分发挥其潜力。路易斯维尔大学非常有资格成为 CCII 的所在地有很多原因，包括我们 10 年进行临床试验的记录 免疫治疗剂、独特的资源，包括从这些试验中获取人体样本、我们的 高级研究人员在癌症免疫学方面的专业知识、我们对转化研究的关注以及影响 COBRE 位于全国癌症死亡率最高的州。重要的是，大学 路易斯维尔市投入巨资使这个拟议的中心取得成功，这一点最好的证明是 五年内机构承诺达 1,680 万美元。 CCII项目的两位PI备受推崇 该领域的专家从基础癌症免疫学到关键癌症免疫学做出了开创性贡献 癌症免疫疗法的临床试验。资深导师在主题领域拥有专业知识和强大的 资助、出版物、指导和研究部门服务的历史将支持 CCII 的指导使命， 具有必要专业知识（管理、生物统计学和生物信息学）的联合研究人员团队也将如此 以及内部和外部咨询委员会。功能免疫组学核心将提供重要的新功能 基础设施并利用现有资源（包括其他 IDeA 计划）提供出色的支持 致四位有前途的初级研究员，他们被选为第一批 CCII 项目 PI。这 CCII 的四个总体具体目标是： (1) 建立行政和指导基础设施 CCII； (2) 创建一个研究核心，在利用现有设施的同时提供新的能力； （三）支持 初级PI在主题领域的研究和职业发展； (4) 制定并启动计划 CCII 的长期可持续性和发展。我们相信，这个新的 COBRE 中心将带来 在头五年内为 4-6 名 CCII 初级研究人员提供创新的 R01 资助，其中许多 毕业生将仍然是这个新 COBRE 的关键成员，以进一步建设该中心的未来。最多 重要的是，我们将严格的基础科学与高度转化的动物和人类标本相结合 研究最终应有助于开发新的治疗策略，这将有助于改善 全球每年被诊断患有癌症的超过 1700 万人的前景。